Annals of Clinical Biochemistry > Volume 45, Number 2 > Pp. 122-128

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Ferns, G. Articles by Keti, V. PubMed PubMed Citation Social Bookmarking                      What's this?

Review Article

HDL-cholesterol modulation and its impact on the management of cardiovascular risk

Gordon Ferns ^1 2  and Vuyolethu Keti ²

¹ Postgraduate Medical School, University of Surrey, Daphne Jackson Road, Guildford, Surrey GU2 7WG, UK; ² Royal Surrey County Hospital, Egerton Road, Guildford, Surrey GU2 7XX, UK

Corresponding author: Prof Gordon Ferns. Email: g.ferns{at}surrey.ac.uk

There is strong epidemiological evidence that HDL-cholesterol (HDL-C) is an independent cardiovascular risk factor. A low HDL-C is a common finding in the general population, and is a feature of metabolic syndrome, the prevalence of which is increasing globally. The importance of HDL-C as a coronary risk factor is generally accepted, and has been incorporated into most of the commonly applied risk engines. There are several causes of a low HDL-C, including rare genetic abnormalities, and more common conditions associated with lifestyle and drug therapy. Not all of these are associated with an increased risk of coronary disease. A better understanding of HDL metabolism and the mechanisms by which it may exert its protective effects has revealed why this may be the case. New therapeutic targets have also been identified that may allow HDL-C to be raised in patients with low levels. However, good clinical endpoint studies are still required to enable the setting of absolute target values for HDL-C in patients at high cardiovascular risk.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?